Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
-quality teaching. The Hub for Applied Bioinformatics (HAB) is the Faculty’s focal point for computational biology, delivering bespoke bioinformatics support and training across genomics, transcriptomics
-
the Faculty of Life Sciences & Medicine Hub for Applied Bioinformatics. This post is jointly funded by the Borne Foundation (50%) and King’s Health Partner’s Centre for Translational Medicine (CTM) (50
-
backgrounds, including computational chemistry, bioinformatics, systems biology, and machine learning. The project offers a unique opportunity to collaborate closely with experimental scientists and contribute
-
that combine deep learning, computer vision, and bioinformatics to extract actionable insights from complex, multi-modal data, including medical imaging, genomics, and clinical records. A central theme of our
-
the Medical Research Council. The Research Fellow will be using Natural Language Processing (NLP) methods, with a special focus on generative Large Language Models (LLMs), to interrogate a very large sample of
-
to develop novel immune therapeutic strategies for hard-to-treat triple negative breast cancers (TNBC). Based in the Cancer Bioinformatics Group (Professor Anita Grigoriadis), the postholder will contribute
-
-quality teaching. The Hub for Applied Bioinformatics (HAB) is the Faculty’s focal point for computational biology, delivering bespoke bioinformatics support and training across genomics, transcriptomics
-
research. We study the fundamental molecular, cellular, and physiological processes that underly normal and abnormal cardiovascular and metabolic function and drive the translation of this strong basic
-
and high-quality teaching. Dr. Alessandra Vigilante leads a research group of bioinformaticians with expertise in multi-omics data integration and translational bioinformatics. She is Head of the Hub
-
cancer organoids from Black male patients. The project will seek to characterise the viability of organoids in response to standard of care chemotherapy and novel agents. In parallel the project will seek